Literature DB >> 21859941

Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment.

María D Macià1, José L Pérez, Soeren Molin, Antonio Oliver.   

Abstract

Biofilm growth, antibiotic resistance, and mutator phenotypes are key components of chronic respiratory infections by Pseudomonas aeruginosa in cystic fibrosis patients. We examined the dynamics of mutator and antibiotic-resistant populations in P. aeruginosa flow-cell biofilms, using fluorescently tagged PAO1 and PAOMS (mutator [mutS] derivative) strains. Two-day-old biofilms were treated with ciprofloxacin (CIP) for 4 days (t4) at 2 μg/ml, which correlated with the mutant prevention concentration (MPC) and provided an AUC/MIC ratio of 384 that should predict therapeutic success. Biofilms were monitored by confocal laser scanning microscopy (CLSM), and the numbers of viable cells and resistant mutants (4- and 16-fold MICs) were determined. Despite optimized pharmacokinetic/pharmacodynamic (PK/PD) parameters, CIP treatment did not suppress resistance development in P. aeruginosa biofilms. One-step resistant mutants (MexCD-OprJ or MexEF-OprN overexpression) were selected for both strains, while two-step resistant mutants (additional GyrA or GyrB mutation) were readily selected only from the mutator strain. CLSM analysis of competition experiments revealed that PAOMS, even when inoculated at a 0.01 proportion, took over the whole biofilm after only 2 days of CIP treatment outnumbering PAO1 by 3 log at t4. Our results show that mutational mechanisms play a major role in biofilm antibiotic resistance and that theoretically optimized PK/PD parameters fail to suppress resistance development, suggesting that the increased antibiotic tolerance driven by the special biofilm physiology and architecture may raise the effective MPC, favoring gradual mutational resistance development, especially in mutator strains. Moreover, the amplification of mutator populations under antibiotic treatment by coselection with resistance mutations is for the first time demonstrated in situ for P. aeruginosa biofilms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859941      PMCID: PMC3195006          DOI: 10.1128/AAC.00617-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  69 in total

Review 1.  Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth.

Authors:  N Høiby; H Krogh Johansen; C Moser; Z Song; O Ciofu; A Kharazmi
Journal:  Microbes Infect       Date:  2001-01       Impact factor: 2.700

Review 2.  Heterogeneity in biofilms.

Authors:  J Wimpenny; W Manz; U Szewzyk
Journal:  FEMS Microbiol Rev       Date:  2000-12       Impact factor: 16.408

3.  Quantification of biofilm structures by the novel computer program COMSTAT.

Authors:  A Heydorn; A T Nielsen; M Hentzer; C Sternberg; M Givskov; B K Ersbøll; S Molin
Journal:  Microbiology       Date:  2000-10       Impact factor: 2.777

Review 4.  The mutant selection window and antimicrobial resistance.

Authors:  Karl Drlica
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

5.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Authors:  Nelson Jumbe; Arnold Louie; Robert Leary; Weiguo Liu; Mark R Deziel; Vincent H Tam; Reetu Bachhawat; Christopher Freeman; James B Kahn; Karen Bush; Michael N Dudley; Michael H Miller; George L Drusano
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 6.  Mechanisms of biofilm resistance to antimicrobial agents.

Authors:  T F Mah; G A O'Toole
Journal:  Trends Microbiol       Date:  2001-01       Impact factor: 17.079

7.  Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants.

Authors:  Patricia Sánchez; Juan Francisco Linares; Beatriz Ruiz-Díez; Ester Campanario; Alfonso Navas; Fernando Baquero; José L Martínez
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

8.  The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants.

Authors:  Antonio Oliver; Fernando Baquero; Jesús Blázquez
Journal:  Mol Microbiol       Date:  2002-03       Impact factor: 3.501

9.  Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants.

Authors:  Mikkel Klausen; Arne Heydorn; Paula Ragas; Lotte Lambertsen; Anders Aaes-Jørgensen; Søren Molin; Tim Tolker-Nielsen
Journal:  Mol Microbiol       Date:  2003-06       Impact factor: 3.501

Review 10.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

View more
  21 in total

1.  Contribution of stress responses to antibiotic tolerance in Pseudomonas aeruginosa biofilms.

Authors:  Philip S Stewart; Michael J Franklin; Kerry S Williamson; James P Folsom; Laura Boegli; Garth A James
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

Review 2.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

3.  Antimicrobial Blue Light Inactivation of Gram-Negative Pathogens in Biofilms: In Vitro and In Vivo Studies.

Authors:  Yucheng Wang; Ximing Wu; Jia Chen; Rehab Amin; Min Lu; Brijesh Bhayana; Jie Zhao; Clinton K Murray; Michael R Hamblin; David C Hooper; Tianhong Dai
Journal:  J Infect Dis       Date:  2016-02-17       Impact factor: 5.226

Review 4.  Biofilm-specific antibiotic tolerance and resistance.

Authors:  I Olsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-29       Impact factor: 3.267

Review 5.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

6.  Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.

Authors:  Estrella Rojo-Molinero; María D Macià; Rosa Rubio; Bartolomé Moyà; Gabriel Cabot; Carla López-Causapé; José L Pérez; Rafael Cantón; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 7.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

8.  Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats.

Authors:  Bruna G S Torres; Victória E Helfer; Priscila M Bernardes; Alexandre José Macedo; Elisabet I Nielsen; Lena E Friberg; Teresa Dalla Costa
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

9.  Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa.

Authors:  Karin Meinike Jørgensen; Tina Wassermann; Peter Østrup Jensen; Wang Hengzuang; Søren Molin; Niels Høiby; Oana Ciofu
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

10.  Evolution of Antibiotic Resistance in Biofilm and Planktonic Pseudomonas aeruginosa Populations Exposed to Subinhibitory Levels of Ciprofloxacin.

Authors:  Marwa N Ahmed; Andreas Porse; Morten Otto Alexander Sommer; Niels Høiby; Oana Ciofu
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.